CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 90 enrolled
Drug / intervention
Ropivacaine +1 moredrug
Likely dose
Ropivacaine 3.75 mg/ml (8 ml) injected intrapleural every 6 hours for 48 hoursAI-extracted
Key inclusion· 3
  • Undergoing thoracotomy for oncologic thoracic surgery
  • Primary or secondary (metastatic) cancer
  • ASA class 1 or 2
Key exclusion· 3
  • Ropivacaine hypersensitivity or allergy
  • Psychiatric disorders
  • Unable to use visual analog scale for pain assessment

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00210132
NCT00210132Phase 2Completed

Randomized Trial to Evaluate the Analgesic Efficacy of Inter Pleural Ropivacaine Road in Post Thoracotomy Pain for Oncologic Surgery

Institut Bergonié·interventional·Posted Sep 21, 2005·Updated Sep 8, 2025

In Brief

A Phase 2 clinical trial evaluating Ropivacaine and Reference for Postoperative Pain and Cancer. Completed, enrolled 90 participants across 1 site.

Detailed Summary

Thoracic surgery via posterolateral thoracotomy causes significant postoperative pain. There are several methods of postoperative pain relief, including intravenous analgesics and local-regional analgesia techniques. Although thoracic epidural remains the gold standard, it is not without complications, which are rare but serious, and should be reserved for trained teams or patients with high morbidity. Intrapleural analgesia is a simple method, performed by the surgeon intraoperatively. Its effectiveness is controversial and the results remain inconsistent. Ropivacaine is a recently marketed local anesthetic with a modest vasoconstrictive effect. The variation in plasma levels of ropivacaine obtained by this technique has not yet been evaluated. The purposes of this study are: 1. To determine the efficacy of inter pleural analgesia 2. To determine the plasmatic concentration of ropivacaine by inter pleural road

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesFrance
Collaborators--

Timeline

Phase 2CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 21, 2005
Enrollment StartOct 1, 2003
Primary CompletionJun 30, 2006
Study CompletionFeb 28, 2008
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 20.8 years ago

Interventions

Ropivacainedrug

ropivacaine at 7.5 mg/ml: 4 ml + 4 ml of saline solution to obtain 8 ml of a ropivacaine solution at 3.75 mg/ml injected into the intrapleural catheter every 6 hours. Treatment administration = every 6 hours for 48 hours.

Referencedrug

8 ml of saline solution will be injected into the intrapleural catheter. Treatment administration = every 6 hours for 48 hours.